At today's price, Cigna's stock implies roughly -2.8% to -1.0% annual free-cash-flow growth for the next ten years — essentially flat to declining — while the company's actual FCF grew 8.6% a year and revenue grew 12.1% a year over the past four years.
At its current price, CI implies roughly -2.8% annual FCF growth for the next 10 years (WACC 9%) — essentially flat or slightly declining.
Cigna's actual FCF growth has averaged +8.6% a year over the past 4 years; revenue grew +12.1% a year over the same span.
-2.8% to -1.0% needed vs. 8.6% actual free-cash-flow growth
Required growth from the reverse DCF below. Historical CAGRs from 10-K FY2021 and FY2025 (FCF grew from $6.04B to $8.39B; revenue from $174.1B to $274.9B, both over 4 years).
How the discount rate changes the answer
| WACC | Required growth |
|---|---|
| 8% | -4.8% |
| 9% (base case) | -2.8% |
| 10% | -1.0% |
| 12% | +2.3% |
Across every discount rate tested, the required growth rate stays at or below the low single digits — nowhere close to Cigna's actual 8.6% FCF pace. This conclusion is unusually insensitive to the discount-rate assumption: no reasonable WACC choice pushes the required rate anywhere near what Cigna has actually delivered.
What would change Cigna's negative-growth answer
- Using 2025's standalone FCF ($8.39B) instead of trailing-twelve-month FCF ($9.11B) as the base nudges the required growth rate up slightly, from -2.8% to -1.7% at a 9% discount rate — health insurers' first-half cash flow tends to run seasonally weaker due to rising receivables, which the TTM figure smooths out.
- Narrowing net debt to only long-term debt (excluding short-term borrowings) would lower net debt further, pushing the required growth rate even lower — implying an even more pessimistic market view.
- Lowering the terminal growth rate from 2.5% to 2.0% would modestly raise the required growth rate, since the discounting effect would compound more heavily over the projection period.
The math behind -2.8% to -1.0%
Inputs, sources, model assumptions, and the calculation
- Share price$276.08 — stockanalysis.com, Aug 31, 2026 close
- Shares outstanding264,240,486 — 10-Q Q2 FY2026 cover page, Jul 24, 2026
- Market cap$72.95B — price × shares (calculated)
- Trailing-twelve-month FCF$9.11B — FY2025 FCF ($8.39B: $9.60B operating cash flow minus $1.21B capex) plus 1H FY2026 FCF ($0.15B) minus 1H FY2025 FCF (-$0.58B)
- Total debt$31.46B — 10-K FY2025 balance sheet (Dec 31, 2025): $0.59B current + $30.87B long-term
- Cash and equivalents$7.68B — 10-K FY2025 balance sheet
- Net debt$23.79B — calculated
- Discount rate (WACC)9% base case (8%/10%/12% tested)
- Terminal growth rate2.5% — long-run GDP-level assumption
Normalization check: the 3-year average FCF (2023-2025) is $9.20B; FY2025's standalone figure ($8.39B) is -8.8% below that average — within the ±40% threshold, so no adjustment was strictly required. Trailing-twelve-month FCF ($9.11B) was used as the representative figure instead, to correct for first-half seasonality typical of a health insurer's cash flow.
Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's target enterprise value (market cap plus net debt).
Historical CAGR check: 4-yr FCF CAGR (2021→2025) = ($8.39B ÷ $6.04B)^(1/4) − 1 = 8.6%. 4-yr revenue CAGR = ($274.9B ÷ $174.1B)^(1/4) − 1 = 12.1%.
Limits of the CI number
- This isn't a fair-value price target — it only shows what the current price already assumes.
- Change the discount rate or the FCF base, and the answer moves somewhat, though the broad conclusion (a very low or negative required growth rate) holds across the range tested — see the sensitivity table above.
- A negative required growth rate doesn't necessarily mean the stock is "cheap" — it may simply reflect that the market has already priced in real risks (PBM rebate regulation, medical cost inflation, large-customer concentration) covered in the snapshot and story pieces above.
- A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
- Any investment decision, and its outcome, is your own responsibility.
What we'd watch next
These three checks would show whether this read is holding up. They are prompts for your own follow-up, not predictions.
- Negative-growth answerThe price implies -2.8% to -1.0%, against 8.6% actual FCF growth.
- Regulatory outcomeA ban on PBM rebates would test this. Follow policy.
- Cash flow durabilityA striking gap suggests the price expects trouble. Ask what.
How this number is built, and how banks, REITs, and negative cash flow are handled: see our methodology.
Frequently asked questions
What growth rate does CI's stock price assume?
At today's price, Cigna's stock implies roughly -2.8% annual free-cash-flow growth for the next ten years at a 9% discount rate — essentially flat to slightly declining cash flow.
How does that compare to Cigna's actual growth?
Cigna's actual free cash flow grew 8.6% a year over the past 4 years, and revenue grew 12.1% a year over the same span — both far above what the current price requires.
What share price was used for this analysis?
This analysis used $276.08, as of the Aug 31, 2026 close.